Norwegian pharmaceutical developer Nycomed continues to be plagued by lower x-ray contrast media prices. The Oslo company this month released first-quarter financial results that showed lower revenues and net income for the period.For the quarter,
Norwegian pharmaceutical developer Nycomed continues to be plagued by lower x-ray contrast media prices. The Oslo company this month released first-quarter financial results that showed lower revenues and net income for the period.
For the quarter, Nycomed had operating revenues of $257.4 million (1.84 billion Norwegian krone), a drop of 7% compared with revenues of $277.4 million in the first quarter of 1996. Nycomed's net income was $25 million, compared with $37 million in the same period last year.
Nycomed said the major factor behind the revenue shortfall was the fact that x-ray contrast media prices in the U.S. were 30% lower in the first quarter of 1997 compared with the first quarter of 1996. Prices, which began dropping early last year, stabilized toward the end of 1996, and remained relatively unchanged in the first quarter of 1997. Additional pressure could be looming, however, as two group purchasing organizations in the U.S. are expected to renegotiate their supply agreements for contrast in the second half of this year.
Nycomed also reported that sales of its Omniscan MRI contrast agent declined in both volume and value in the U.S. compared with the first quarter of 1996, while price pressure also hit the MRI contrast market. Omniscan sales outside the U.S. grew 30%, however.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.